ORPHAN TECHNOLOGIES

Orphan Technologies is committed to reduce the burden of patients suffering from homocystinuria. OT-58, their lead drug development candidate, has been optimized as an enzyme replacement therapy for classical homocystinuria, a genetic disease characterized by debilitating cardiovascular, skeletal, neurologic, and ophthalmologic complications. OT-58 is designed to reduce homocysteine levels via a targeted mechanism of action and may have therapeutic applications in other diseases.

#SimilarOrganizations #Website #More

ORPHAN TECHNOLOGIES

Industry:

Address:

Rapperswil, Zurich, Switzerland

Country:

Switzerland

Website Url:

http://www.orphantechnologies.com

Status:

Active

Email Addresses:

[email protected]

Technology used in webpage:

Domain Not Resolving Amazon Google Apps For Business ReCAPTCHA GoDaddy DNS ReCAPTCHA V2 Amazon Frankfurt Region Media Temple

Similar Organizations

affini-t-therapeutics-logo

Affini-T Therapeutics

Affini-T Therapeutics is a biotechnology company developing T-cell therapies for patients suffering from cancer.

chaperone-therapeutics-logo

Chaperone Therapeutics

Chaperone Therapeutics is developing frontline therapies to address diseases of protein misfolding

lannett-company-logo

Lannett Company

Lannett develops, manufactures, and distributes generic prescription pharmaceutical products in tablet.

Official Site Inspections

http://www.orphantechnologies.com

Host Informations
Whois Informations

Loading ...

More informations about "Orphan Technologies" on Search Engine